Earnings Feed
Start Free
Home/Filings/4/0000950170-24-068770
4//SEC Filing

Prudo-Chlebosz Raymond 4

Accession 0000950170-24-068770

CIK 0001541157other
View on SEC.govCompany Profile

Filed

Jun 3, 8:00 PM ET

Accepted

Jun 4, 4:45 PM ET

Size

24.6 KB

Accession

0000950170-24-068770

Insider Transaction Report

Form 4
Period: 2024-05-31
Akari Therapeutics PlcAKTX
Prudo-Chlebosz Raymond
Director
Transactions
  • Award

    Warrants (Right to Buy)

    2024-05-31$0.00/sh+1,326,258,000$1,193,632→ 1,326,258,000 total
    Exercise: $0.00From: 2024-05-31Exp: 2027-05-31→ Ordinary Shares, par value $0.0001 per share (1,326,258,000 underlying)
  • Award

    Ordinary Shares, par value $0.0001 per share

    2024-05-31$0.00/sh+1,326,258,000$1,193,632→ 3,657,838,600 total
Holdings

  • Ordinary Shares, par value $0.0001 per share

    (indirect: By Trust)
    38,709,600

  • Ordinary Shares, par value $0.0001 per share

    (indirect: RPC Pharma Limited)
    800,766,600
Footnotes (3)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
  • [F2]On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant.
  • [F3]The warrants have an exercise price of $0.000895 per Ordinary Share.

Documents

2 files

Issuer

Akari Therapeutics Plc

CIK 0001541157

→
Entity typeother

Related Parties

1
  • filerCIK 0001653262

Filing Metadata

Form type
4
Filed
Jun 3, 8:00 PM ET
Accepted
Jun 4, 4:45 PM ET
Size
24.6 KB
View on SEC.gov